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Abstract
Herein, we report an efficient combinatorial therapy for metastatic ovarian cancer based on
siRNA-mediated suppression of DJ-1 protein combined with a low dose of cisplatin. DJ-1
protein modulates, either directly or indirectly, different oncogenic pathways that support and
promote survival, growth, and invasion of ovarian cancer cells. To evaluate the potential of this
novel therapy, we have engineered a cancer-targeted nanoplatform and validated that DJ-1
siRNA delivered by this nanoplatform after intraperitoneal injection efficiently downregulates
the DJ-1 protein in metastatic ovarian cancer tumors and ascites. In vivo experiments revealed
that DJ-1 siRNA monotherapy outperformed cisplatin alone by inhibiting tumor growth and
increasing survival of mice with metastatic ovarian cancer. Finally, three cycles of siRNAmediated DJ-1 therapy in combination with a low dose of cisplatin completely eradicated ovarian
cancer tumors from the mice, and there was no cancer recurrence detected for the duration of the
study, which lasted 35 weeks.
Keywords: ovarian cancer, DJ-1, cisplatin, combinatorial therapy, siRNA
Abbreviations: IV chemotherapy – intravenous chemotherapy; IP chemotherapy – intraperitoneal
chemotherapy; PTEN - phosphatase and tensin homolog; p53 - tumor suppressor protein 53;
NRF2 - nuclear factor (erythroid-derived 2)-like 2; ROS - reactive oxygen species; PPIG4 Generation 4 poly(propylene imine) dendrimer; MAL-PEG-NHS - α-Maleimide-ω-Nhydroxysuccinimide ester poly(ethylene glycol), LHRH - Luteinizing Hormone-Releasing
Hormone; qPCR - real-time quantitative polymerase chain reaction; ES-2-luc - luciferaseexpressing ES-2 human ovarian cancer cells; NRS – normal rabbit serum; PBS - phosphate
buffered saline; PEG - polyethylene glycol; p-Akt - phosphorylated Akt, LRT - Likelihood Ratio
Test; CI – confidence interval; SD - standard deviation.
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Introduction
Ovarian cancer is the deadliest gynecologic malignancy.1 The high mortality of ovarian cancer
stems from its unique metastatic behavior not shared with other cancers. Following exfoliation at
primary tumor sites, ovarian cancer cells are disseminated within the abdominal cavity via a
peritoneal fluid.2, 3 As a result, malignant cells encase the reproductive organs, bladder, sigmoid
colon, and omentum, leading to the accumulation of abdominal ascites and severe pain.3 The
standard therapy for patients with metastatic ovarian cancer consists of primary debulking
surgery followed by platinum-taxane based chemotherapy.1,

4

Due to the diffuse nature of

ovarian cancer, surgery rarely enables the complete removal of all metastases, and the
incorporation of chemotherapy is of utmost importance to eliminate any residual tumors.4, 5 The
standard chemotherapy regimen for ovarian cancer is a combination of two or more platinum and
taxane drugs administered intravenously (IV) or intraperitoneally (IP) for three to six cycles.6
Application of multiple chemotherapeutic agents allows the oncologists to target a variety of
oncogenic pathways that promote growth and dissemination of primary tumor in the form of
metastases. Clinical studies revealed that IP chemotherapy is more efficient than IV
chemotherapy, but it also causes more deleterious side effects making some patients discontinue
their treatment before its completion.7 Enhanced therapeutic efficacy and the severe side effects
that encompass IP chemotherapy are due to the high concentrations of the chemotherapeutic
agents that can be achieved within the peritoneal cavity.7 Therefore, there is an urgent need to
develop novel IP therapies that allow for a reduction in the number of cycles and doses of
chemotherapeutic drugs used in the treatment of ovarian cancer, while improving treatment
outcomes and efficacy. Identification and suppression of a single multifunctional protein,

4
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responsible for malignant proliferation, invasion, chemoresistance, and overall cellular survival,
is a promising therapeutic avenue that would satisfy all the aforementioned needs.
DJ-1 is a multifunctional protein that has recently been implicated as a key oncogenic driver and
biomarker for various cancers, including ovarian cancer.8, 9 Previous studies revealed that DJ-1 is
expressed in more than 80% of cases of advanced ovarian carcinoma at all anatomical sites.10 It
was also documented that increased DJ-1 expression positively correlates with both lower
survival in ovarian cancer patients and enhanced the resistance of ovarian cancer cells to
platinum-based drugs.11-13 DJ-1 has been shown to modulate (either directly or indirectly)
various cellular pathways that support and promote survival, growth, and invasion of cancer
cells.12,13 It is known that DJ-1 binds to and downregulates the activity of phosphatase and tensin
homolog (PTEN), a protein that functions as a biological brake for Akt pathways, thus increasing
the growth, proliferation, and migration of tumor cells.8, 14, 15 Furthermore, DJ-1 directly inhibits
tumor suppressor protein 53 (p53), a cell cycle regulation protein responsible for cell cycle
arrest.16 DJ-1 enhances the activity of NRF2 - an antioxidant protein that, when translocated to
the nucleus, upregulates a cohort of factors responsible for modulating the cellular redox
homeostasis in response to elevated levels of intracellular reactive oxygen species (ROS).17-19
Finally, DJ-1 upregulates glutamate cysteine ligase - the rate-limiting enzyme in glutathione
synthesis further increasing cellular antioxidant defenses.20
We have recently demonstrated in vitro that DJ-1 is highly overexpressed in ovarian cancer cells
and its siRNA-mediated suppression substantially decreases cell proliferation, viability, and
migration.11 Moreover, we discovered that DJ-1 suppression in combination with a low dose of
cisplatin provides a superior therapeutic response in the studied ovarian cancer cell lines.11
Therefore, we hypothesized that novel IP therapy based on siRNA-mediated DJ-1 suppression
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combined with low doses of cisplatin could provide a promising treatment modality for
metastatic ovarian cancer. Herein, we report the first use of DJ-1 suppression as a therapeutic
approach for the treatment of metastatic ovarian cancer.
Methods
Development of a murine model for metastatic human ovarian cancer
Animal studies were performed according to the Humane Care and Use of Laboratory Animals
Policy and were approved by Institutional Animal Care and Use Committee of Oregon Health
and Science University. Experiments were carried out on female Nu/Nu Nude mice bearing
intraperitoneal xenograft of luciferase-expressing ES-2 (ES-2-luc) human ovarian cancer cells
(Supplementary materials).
Synthesis and characterization of a nanoplatform for siRNA delivery
The LHRH-targeted nanoplatform for DJ-1 siRNA delivery was prepared and characterized
according to our developed procedures (Supplementary Materials).11, 19, 21
Evaluation of the nanoplatform efficiency to suppress the targeted protein in vivo
Three weeks following ES-2-luc inoculation, five mice were IP injected twice per week
(Tuesday and Friday) with 0.5 mL of nanoparticles loaded with DJ-1 siRNA at a 50 μM
concentration. In the control group, five mice were injected with saline. 24 h after the second
injection, mice were euthanized, and both solid tumors and ascites fluid were collected. A
portion of the solid tumors was digested using a tissue homogenizer in 250 μL of RIPA buffer.
The ascites cells were centrifuged at 3,500 rpm for 3 min, and the cell pellet resuspended in 250
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μL of RIPA buffer. The immunoblots were performed according to our previously published
protocol.11, 19
Animals dosing regimen
The control and cisplatin monotherapy groups were IP dosed once a week at the beginning of
each week (Monday). The control group was given a normal saline injection at a volume of 1
mL. The cisplatin monotherapy group was given an IP injection of cisplatin at a concentration of
0.05 mg (1.85 mg/kg), in a volume of 1 mL. Finally, the DJ-1 monotherapy group was IP dosed
twice per week (Tuesday and Friday) with nanoparticles at a 50 μM siRNA concentration in a
volume of 0.5 mL. For the combinatorial treatment group, the cisplatin and DJ-1 monotherapy
groups dosing regimens were combined. All treatment groups were given their respective
therapies for a total of 3 weeks.
Statistical Analysis
The data were analyzed using descriptive statistics and presented as mean values ± standard
deviation (SD) from 3-6 independent measurements. The comparison among groups was
performed by the independent sample Student’s t-test. The difference between variants was
considered significant at p < 0.05. Kaplan-Meier estimator curves and median survival times
were performed using "survfit" in the "survival" R package. Log-Rank-Test for differences
between groups was performed using "survdiff" in "survival." Hazard ratios for treatments and
overall Likelihood Ratio Test were calculated using "coxph" in "survival." The proportional
hazards assumptions were confirmed using the Z:ph test "cox.zph" in "survival."
Results
Development and characterization of a murine model for metastatic human ovarian cancer
7

To validate the therapeutic efficacy of the novel IP therapy, we established a murine model of
metastatic ovarian cancer by inoculating ES-2 human ovarian clear cell carcinoma cells, into the
peritoneal cavity of nude mice. Cancer progression in the mouse’s body was monitored by
recording the bioluminescence signal generated by ES-2 cells that are stably transfected with a
luciferase reporter gene (Figure 1 A-D). ES-2 cells were selected based on five key intrinsic
features required to rigorously evaluate the efficacy of the proposed treatment on an aggressive
ovarian metastatic cancer model.
First, ES-2 cells are classified as an ovarian clear cell carcinoma, which is an aggressive subtype
of epithelial ovarian cancer (EOC) characterized by poor response to platinum-based drugs, high
recurrence, and lower survival rates when compared to other types of EOC.22, 23 Therefore, novel
treatment modalities such as the developed therapy are highly warranted to increase the survival
rate of patients with advanced ovarian clear cell carcinoma.23
Second, ES-2 cells have a rapid growth rate, with a doubling time of ~19 hours.11,

24

Consequently, they could be employed to develop an animal model of aggressive ovarian cancer
that mimics the abdominal metastasis and ascites formation observed in patients with stage III
and IV ovarian cancer. Our studies validated the aggressive nature of ES-2 cells inoculated into
the peritoneal cavity of mice. The cancer’s dissemination within the peritoneal cavity was rapid
and mice had to be euthanized at the end of week 4 following ES-2 cell injection due to lethargy
and mobility issues caused by a dramatic accumulation of ascites fluid leading to a marked
increase in body weight and visible external tumors protruding from the lower abdomen (Figure
1A-E). Peritoneal lavage was performed in euthanized mice to evaluate the dissemination of the
solid tumors. By using bioluminescence imaging and visual techniques, we confirmed that tumor
nodules were disseminated widely through the peritoneal cavity and attached to various organs
8
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including liver, colon and gastrointestinal tract (Figure 1 C and D). Of note, the average volume
of ascites fluid was about 5 mL per animal.
Third, we have previously demonstrated that ES-2 cells overexpress the DJ-1 protein, a main
target of the proposed

therapy.11 In the current study, DJ-1 overexpression has also been

confirmed in both solid tumors and the cells collected from the ascites fluid by qPCR and
immunoblot analyses (Figure 1F). In addition, the basal level of DJ-1 mRNA was 2.3 times
higher in ascites relative to solid tumors. To the best of our knowledge, this is the first report
demonstrating differential expression of DJ-1 in solid tumors and malignant ascites. This
correlation could be related to the fact that malignant ascites-derived cells exhibit enhanced
resistance to chemotherapies, and increased metastatic potential.25 Thus, differential expression
of key oncogenic drivers such as DJ-1 is expected. Similarly, Mo et al. demonstrated that
expression of the ABC transporters (MDR1, MRP1, and BCRP) associated with chemoresistance
was significantly higher in ascites-derived human ovarian cancer cells when compared to cells
derived from primary tumor.26
Fourth, ES-2 cells exhibit moderate resistance to platinum chemotherapeutic agents.11,

24

Platinum resistance is of an immense clinical importance as it has been reported that a majority
of patients with cancer relapse show either a decreased sensitivity or complete resistance to
platinum chemotherapy.27
Fifth, ES-2 cells have been shown to overexpress the luteinizing hormone releasing hormone
receptor (LHRHR) used for growth and proliferation.28 Therefore, our nanoparticles, equipped
with the targeting LHRH peptide, can be used to efficiently deliver DJ-1 siRNA to ES-2 tumors
after IP administration.11 LHRHR are expressed in about 80% of endometrial and ovarian
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cancers, as well as other cancers.29-33 Shah et al. demonstrated that metastatic and primary
tumors collected from advanced ovarian carcinoma patients as well as cancer cells isolated from
malignant ascites overexpressed LHRHR, while expression of this receptor in other organs was
minimal or undetectable.34 We anticipate the LHRH-targeted nanoplatform prepared and
evaluated in the present study can be potentially extended to a variety of ovarian tumors.
Synthesis and characterization of a nanoplatform for siRNA delivery
The instability in blood and low accumulation in the targeted tissue after systemic administration
and limited internalization into cellular cytoplasm are the major issues preventing the application
of siRNA for the developed therapeutic approach.35 Therefore, we have engineered a delivery
system for the transportation of the DJ-1 siRNA to the ovarian cancer tumors after IP
administration (Figure 2). The core of the system is based on the nanoparticles formed as a result
of the spontaneous electrostatic complexation between the DJ-1 siRNA and generation 4 PPI
dendrimer (PPI G4).36 The positively charged primary amines of the PPI G4 interact with the
negatively charged phosphate groups of the siRNA’s backbone (Figure 2A). An excess of the
dendrimer provides encapsulation of siRNA inside of nanoparticles, which in turn protects the
siRNA against Ribonuclease-mediated degradation in the serum and facilitates cellular uptake.21
The gel retardation assay validated the complete complexation of the siRNA by PPI G4 at
nitrogen to phosphate (N/P) ratio of 2 (Figure S1), indicating that the resulting nanoparticles
contain 0.38 nanomoles of siRNA per 1 nanomole of PPI G4. According to DLS analysis, the
formed nanoparticles featured an average hydrodynamic diameter of 100.8 ± 15.5 nm (Figure
S2) and a narrow size distribution (polydispersity index (PDI) = 0.13 ± 0.07). The protonated
amines in the dendrimer structure, which are important for siRNA complexation, introduce
positive charge onto the surface of nanoparticles (+28.0 ± 4.1 mV). A positively charged surface
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could promote nanoparticle aggregation in the blood, due to electrostatic association with
negatively charged serum proteins.37,

38

To avoid this, we have modified the surface of

nanoparticles with polyethylene glycol (PEG), which contains a thiol-reactive maleimide and
amine-reactive NHS ester on the opposite ends.21 The modification has been carried out by
coupling NHS groups of PEG to amino groups on the nanoparticle surface via amide bonds
(Figure 2B). Finally, the LHRH peptide was conjugated to the distal end of the PEG moiety by
coupling its MAL group to a thiol group (SH) presented in the peptide structure (Figure 2C).21
The presence of LHRH peptide on the nanoparticles surface was confirmed by Bicinchoninic
acid protein assay according to the manufacturer’s protocol and our published procedure.21 The
obtained results revealed that the nanoparticles loaded with 50 nanomoles of siRNA are modified
with 1.6 moles of the LHRH peptide. The resulting nanoparticles have a hydrodynamic
diameter of 145.2 ± 9.1 nm with a PDI of 0.18 ± 0.02 (Figure S2), and slightly positive surface
charge (+7.7 ± 1.6 mV).
Since premature release of siRNA molecules from the delivery system following IP
administration could compromise their therapeutic efficacy, we evaluated the stability of
nanoparticles in terms of siRNA release in ascitic fluid. The obtained data demonstrates that less
than 10% of encapsulated siRNA molecules were released within 48 h (Figure S3).
We evaluated the tumor targeting capability of both non- and LHRH-modified nanoparticles
following their IP administration into mice with intraperitoneal xenografts of ovarian cancer
(Figure 3A-D). The IVIS imaging system (PerkinElmer, Waltham, MA, USA) was used to
monitor bioluminescence representing dissemination of luciferase-expressing cancer cells as well
as NIR fluorescence generated by the Cy5.5-labeled siRNA. The recorded fluorescence images
revealed that siRNA molecules delivered by both non- and LHRH-targeted nanoparticles were
11
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distributed in the abdominal cavities 24 h after IP injection (Figure 3B and D). Furthermore,
comparison of bioluminescence and fluorescence images indicates a strong overlap between
bioluminescence and fluorescence signals, generated by cancer cells and Cy5.5-labeled siRNA
delivered with LHRH-targeted nanoparticles, respectively (Figure 3C and D). Quantitative
analysis confirmed that fluorescence intensity of Cy5.5-labeled siRNA overlapped with
bioluminescence was 2.3 times higher in case of LHRH-targeted nanoparticles when compared
to non-targeted (PEG-modified) ones, suggesting that LHRH peptide molecules enhance
accumulation of the nanoparticles in the cancer tumors. The obtained in vivo data is in good
agreement with our published in vitro results that demonstrated the ability of LHRH peptide to
improve internalization of the nanoparticles into the ovarian cancer cells.11
To assess the potential acute toxicity of the LHRH-targeting nanoplatform, healthy mice were
treated with the DJ-1 siRNA-loaded nanoparticles during four weeks (eight IP injections, three
days apart) and the concentrations of surrogate markers in blood for kidney function (blood urea
nitrogen (BUN) and creatinine (Cr)) and liver function (alanine transaminase (ALT) and alkaline
phosphatase (ALP)) were measured at the end of the treatment (Figure 3E and F).39 In addition,
the serum levels of blood electrolytes were evaluated as an indicator of major organ toxicity
(Figure 3G).40 The concentrations of surrogate markers and blood electrolytes in mice injected
with saline (control) or the nanoparticles were similar (Figure 3E and G) and within the normal
ranges,41 indicating that the developed nanoparticles do not exhibit any acute toxicity.
The DJ-1 siRNA’s ability to suppress the targeted protein in both solid tumors and ascites was
evaluated in mice inoculated with ES-2 cells 3 weeks before nanoparticle administration. Ascites
and solid tumors were collected after one round of siRNA therapy (two IP injections, 3 days
apart) and DJ-1 protein levels were analyzed by immunoblotting and compared to the cancer
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samples obtained from animals injected with saline. The results revealed that siRNA delivered
by our nanoparticles significantly decreases DJ-1 basal levels in both ascites and solid tumors
(Figure 4 and Figure S4). Of note, DJ-1 suppression was more efficient in ascites as compared to
solid tumors. The observed difference is likely due to the fact that ascites acts as a physiological
barrier between the injected therapy and the solid tumors. Consequently, the cells within the
ascites fluid absorb a substantial portion of the injected nanoparticles before they can reach solid
tumors. These results reinforce the importance of both the timing of treatment, and the removal
of abdominal ascites before the commencement of therapy.
We also evaluated changes in the expression of critical oncogenic proteins modulated by DJ-1
such as p-Akt, NRF2, and p53, following IP administration of the nanoparticles. Previous studies
demonstrated that DJ-1 protein enhances Akt phosphorylation by binding to PTEN and thereby
promoting proliferation and migration of cancer cells.8, 14, 15 Overexpression of DJ-1 also results
in elevated levels of NRF2 that induces expression of various antioxidant factors, thereby
protecting cancer cells from ROS-mediated cell death.11, 20, 42 Indeed, the immunoblot analyses
confirmed that basal levels of p-Akt and NRF2 were downregulated in both solid tumors and
cells isolated from ascites fluid after siRNA-mediated DJ-1 suppression (Figure 4 and Figure
S4). DJ-1 has also been reported to promote cancer cells growth and resistance to
chemotherapeutic drugs by sequestering tumor suppressor protein p53 and consequently
inhibiting the apoptotic p53-Bax-Caspase pathway.8, 11, 16 It was consistently observed that the
levels of p53 and pro-apoptotic cleaved caspase 3 (CASP-3) were substantially elevated in both
ascites and solid tumors following the siRNA-mediated attenuation of DJ-1 (Figure 4 and Figure
S4). Moreover, changes in the expression of the above-mentioned proteins in solid tumors were
confirmed by immunohistochemistry (Figure S5).
13
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Design and evaluation of the combinatorial therapy for metastatic ovarian cancer
The developed combinatorial treatment consists of two monotherapies administered sequentially
via IP route for three cycles: (1) the chemotherapy agent, cisplatin, and (2) siRNA-loaded
nanoparticles aimed to suppress DJ-1 protein (Figure 5).
For the treatment of Stage III and IV ovarian cancer in a clinical setting, IP administration of
cisplatin (75 mg/m2) is recommended to be given on day one of each cycle and must be
incorporated with the use of IV paclitaxel or cyclophosphamide for a treatment duration of 6
cycles.43 Our strategy for developing the new IP treatment modality has been to use a single
chemotherapeutic agent below its recommended therapeutic dose and decrease the number of
treatment cycles from six to three in order to minimize severe side effects of conventional IP
chemotherapy. Based on the recommended 75 mg/m2 dose, an average woman with a weight of
60 kg and body surface area (BSA) of 1.62 m2 would require an IP injection of ~120 mg (2
mg/kg) cisplatin.44 By assuming an equivalent surface area dosage conversion factor of 12.3,44
the IP does of ~ 0.5 mg (~25 mg/kg) cisplatin would be expected for a mouse with a BSA of
approximately 0.007 m2. We reduced the last mentioned IP dose of cisplatin for our therapy by a
factor of 10 resulting in 0.05 mg (1.85 mg/kg), which is reported to be safe in nude mice.45. In
considering the accepted dosing regimen, scaled for species’ size variability, the combinatorial
treatment included an IP injection of cisplatin dosed at 0.05 mg (1.85 mg/kg) once a week for 3
weeks (three cycles) on day one of each cycle (Monday, Figure 5).
Our in vitro studies demonstrated that siRNA therapy must be initiated prior to cisplatin
administration in order to achieve the superior therapeutic outcome (Figure S6). Such regimen is
due to the long half-life (~24-30 h) of DJ-1;17,

14
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thus siRNA-mediated silencing of DJ-1
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transcript is needed before chemotherapy to substantially deplete its basal levels in cancer cells.
To achieve and maintain steady-state suppression of DJ-1 protein, siRNA therapy was initiated
one week prior to, and continued during cisplatin-based chemotherapy via IP injections of
siRNA-loaded nanoparticles on Tuesday and Friday of each week during 3 weeks (total of 6
injections, Figure 5). Our in vivo data provided in Figure 4 validates that two IP injections of
siRNA-loaded nanoparticles administered 3 days apart provided a substantial decrease of DJ-1
protein levels in both solid tumors and ascites. The siRNA dosing regimen was based on our
previous in vitro data, which demonstrated that following one siRNA transfection, DJ-1 protein
suppression lasts for more than 3 days in cultured ovarian cancer cells.11
The efficacy of our combinatorial therapy was assessed by long-term survival studies and
compared to the corresponding monotherapies and non-treated animals. The following control
groups were tested (Figure 5): (1) no treatment: one IP injection of saline on Monday of each
treatment week (total of 3 injections); (2) cisplatin monotherapy: one IP injection of cisplatin
(Cis) on Monday of each treatment week (total of 3 injections); and (3) siRNA monotherapy:
two IP injections of siRNA-loaded nanoparticles on Tuesday and Friday of each treatment week
(total of 6 injections). All treatments were initiated one week after inoculation of ES-2 ovarian
cancer cells into mice and animals were monitored for fitness and survival during the study.
Additonally, both body weight and bioluminescence images of mice were recorded weekly.
Three weeks following treatment initiation, mice injected with saline displayed signs of severe
ascites characterized by obvious abdominal distension, the rapid increase in body weight (Figure
S7), lethargy and impaired mobility. Also, the tumors were widely disseminated accross the
abdominal cavity as indicated by bioluminescence imaging (Figure 6). Consequently, animals
had to be euthanized according to the approved protocol. The cisplatin monotherapy prolonged
15
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the median survival time of mice to 6 weeks whereas that of the saline-treated group was 3
weeks after the start of treatment (Table 1, Figures 6 and 7). Interestingly, the siRNA
monotherapy further extended the survival time of mice by 2 weeks over that of cisplatin alone.
Finally, ovarian cancer tumors were completely eradicated from the mice treated with a
combinatorial therapy, and there was no cancer recurrence detected during the duration of
experiment (Figure 6). The animals from this group were observed for 35 weeks and euthanized.
Because a single non-cancer-related death occurred in this group, median survival time could not
be calculated but would be greater than 35 weeks (Figure 7 and Table 1).
Hazard Ratios, a measure of the effect of treatment on an outcome of interest over time, were
calculated for each group. Cisplatin monotherapy displayed a Hazard Ratio of 0.10306 (95% CI:
0.02151-0.49365), a reduction in the hazard (death probability at a given time point) by 89.7%
compared to saline-treated animals (Table 1). Cisplatin-treated mice at any given time point
during the study were 89.7% less likely to die at the next time point compared with mice in the
saline treated group. The siRNA monotherapy and combinatorial treatment displayed Hazard
Ratios of 0.00893 (95% CI: 0.00072-0.11120) and 0.00092 (95% CI: 0.00003-0.03296), showing
a reduction in the hazard by 99.1% and 99.9%, respectively (Table 1). Mice treated with siRNAloaded nanoparticles and combinatorial treatment at any given time point during the study were
99.1% and 99.9% less likely to die at the following time point compared to mice in the saline
treated group, respectively. The calculated hazard ratios show that the combinatorial therapy had
the greatest reduction in hazard of all the treatment groups, meaning that cisplatin combined with
DJ-1 siRNA has the most pronounced effect on ovarian cancer cell death leading to increased
survival within the combinatorial group. An overall difference between the four treatment groups
was found to be significant (LRT: 2=25, df=3, p=1.57e-05). Within the Cox-Proportional
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Hazards Model, both treatments were considered significant (Cisplatin monotherapy: Z=-2.84,
p=0.00447; siRNA monotherapy: Z=-3.67, p=0.00025), with the overall model significance
(LRT=29.3, df=2, p=4.37e-07).

Discussion
An efficient approach for ovarian cancer treatment can be developed by combining two or more
therapeutic agents at their non-toxic doses in a manner wherein cytotoxic mechanisms of action
synergistically complement each other ideally affecting multiple pathways that lead to the cancer
growth and survival. Here, we have combined the first line chemotherapy agent cisplatin and a
novel siRNA-based gene therapy focused on the suppression of the multifunctional DJ-1 protein.
Their cytotoxic mechanisms of action target multiple distinctly different intracellular pathways
and thus make it extremely difficult for the cancer cells to compensate and upregulate antiapoptotic pathways in order to survive. Cisplatin primarily stops the proliferation of cancer cells
by crosslinking DNA, usually at guanine residues, thereby disrupting DNA repair mechanisms,
causing DNA damage, and subsequently inducing apoptosis when repair proves impossible.47
Several studies also reported that cisplatin can induce an intracellular level of toxic ROS via the
reduction of the mitochondrial membrane potential.11, 48 In contrast to cisplatin, DJ-1 suppression
by siRNA can simultaneously interfere with the expression of multiple oncogenic proteins
responsible for ovarian cancer cells survival, migration, proliferation, and resistance to platinumbased drugs.8 Our data indicate that DJ-1 silencing correlates with a significant upregulation of
p53 in tumors and ascites, a protein that negatively affects proliferation and viability of
malignant cells.8, 16 We also validated that siRNA-mediated DJ-1 suppression is accompanied by
downregulation of p-Akt levels. Akt phosphorylation promotes survival and migration of cancer
17
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cells while reducing their apoptosis.

8, 14, 15

Finally, we revealed that DJ-1 suppression leads to a

substantial reduction in the intracellular level of NRF2. It is known that enhanced levels of NRF2
protect cancer cells from ROS-mediated death.20, 42
Our present in vivo data suggests that siRNA-mediated suppression of DJ-1 can be a potent
strategy to enhance the anticancer effects of conventional chemotherapy while reducing severe
side effects. Taking advantage of the prepared nanoplatform, we demonstrated for the first time
that DJ-1 siRNA downregulates the targeting protein in metastatic ovarian cancer tumors and
ascites following IP injection. DJ-1 siRNA monotherapy outperformed cisplatin-based treatment
by inhibiting tumor growth and increasing survival of mice by two weeks. The superior
therapeutic effect could be attributed to the fact that siRNA-mediated DJ-1 suppression disrupts
more oncogenic pathways in ovarian cancer cells when compared to cisplatin alone.11 Our in
vivo results are in good agreement with previously published in vitro data indicating that DJ-1
siRNA monotherapy provides higher efficacy than cisplatin regarding decreasing cancer cells
viability, proliferation, and migration while enhancing intracellular ROS production and cell
cycle arrest.11 Although treatment of mice with metastatic ovarian cancer by DJ-1 siRNA
monotherapy significantly reduced the growth rate of tumors in comparison to cisplatin
treatment, complete remission of cancer was not attained and mice had to be euthanized at the
end of week 8. The observed therapeutic outcome could be explained by the fact that siRNA
treatment was completed at the end of week 3 and due to only temporary effects of siRNAs on
target genes (several days).11, 12 As a result, DJ-1 protein suppression by three cycles of siRNA
therapy may not last long enough to kill all the cancer cells. In contrast, combinatorial siRNAmediated DJ-1 therapy with a low dose of cisplatin completely eradicated ovarian cancer tumors
from the mice, and no cancer recurrence was detected during the 35-weeks trial. These results
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strongly suggest that the suppression of DJ-1 protein may dramatically enhance the therapeutic
activity of cisplatin and could be explored as a therapeutic target in combination with other
chemotherapy agents.
In conclusion, this work validates therapeutic efficacy of a novel combinatorial treatment for
metastatic ovarian cancer and highlights the importance of selecting therapeutic agents whose
cytotoxic mechanisms of action complement one another in the context of a treatment regimen.
Our animal studies establish a solid foundation for the potential application of DJ-1 siRNA
therapy as an adjuvant therapeutic option

to reinforce the existing conventional

chemotherapeutic regimens in order to attain decreased systemic side effects and increase the
efficacy of traditional anti-cancer interventions.
Appendix A. Supplementary Materials
Supplementary materials to this article can be found online.
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FIGURE LEGENDS:
Figure 1. Murine model of metastatic ovarian cancer. Representative photographs (A and C) and
bioluminescence images (B and D) of a mouse 4 weeks after IP injection with ES-2-luc ovarian
cancer cells. (C) Arrows indicate cancer tissues. (E) Changes in body weight of mice injected
with ES-2-luc cells (black line) when compared to mice without cancer (red line). (F) Basal
levels of DJ-1 mRNA in solid ovarian cancer tumors and ascites obtained from mice 4 weeks
post ES-2-luc cells inoculation. The intracellular level of DJ-1 mRNA in solid tumors was set to
1. *p < 0.05 when compared with solid tumors. Inset: Representative western blot images of DJ1 protein and β-actin expression in solid cancer tumors and ascites.

Figure 2. Preparation of siRNA-loaded nanoplatform. (A) Complexation of negatively charged
siRNA by positively charged PPI G4 dendrimers into nanoparticles. (B) Modification of the
siRNA-loaded nanoparticles by conjugation of NHS-activated PEG to dendrimer amino groups
on the nanoparticle surface via an amide bond. (C) Conjugation of LHRH peptide to the distal
end of PEG layer through the maleimide groups on PEG and the thiol groups in LHRH.

Figure 3. Distribution of bioluminescence (A and C) and Cy5.5-siRNA-generated fluorescence
(B and D) 24 h after IP injection of non-targeted (A and B) and LHRH-targeted (C and D)
nanoparticles into mice with intraperitoneal xenograft of ES2 ovarian cancer cells. Note: only
cancer tissues generate bioluminescence signal in D-luciferin-injected animals. The blood levels
of BUN and creatinine (E), ALT and ALP (F), and (G) electrolytes (sodium (Na), potassium
(K), chloride (Cl), calcium (Ca), phosphorus (P)) in mice injected IP with saline (control) and
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DJ-1 siRNA-loaded nanoparticles (nanoplatform, a 50 μM siRNA concentration in a volume of
0.5 mL) during four weeks (total eight injections, three days apart).

Figure 4. Representative western blot images of DJ-1, p-Akt, NRF2, p53 and CASP-3
expression in both ascites and solid tumors collected from the mice after treatment with saline
(control) and nanoparticles loaded with DJ-1 siRNA. β-Actin was used as the loading control.

Figure 5. The schematic shows treatment schedules for the combinatorial therapy and
corresponding monotherapies.

Figure 6. Representative whole-body bioluminescence images of ES-2-luc tumor-bearing nude
mice at various time points after treatment with saline (no treatment), cisplatin, DJ-1 siRNAloaded nanoparticles (siRNA) and combinatorial therapy. Note: only cancer tissues and ascites
generate bioluminescence signal in D-luciferin-injected animals.

Figure 7. Kaplan-Meier survival curves of ES-2-luc tumor-bearing nude mice after treatment
with saline (no treatment), cisplatin, DJ-1 siRNA-loaded nanoparticles (siRNA) and
combinatorial therapy.
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Table 1. Parameters from survival studies
Median survival
Therapy
time (weeks)

Hazard ratio
*
(95% CI)

Reduction in the hazard#

Saline

3

Cisplatin

6

0.10306

89.7%

DJ-1 siRNA

8

0.00893

99.1%

>35

0.00092

99.9%

Combinatorial
*

Compared to saline-treated group
Reduction in the probability of death at a given time point compared to saline-treated animals

#
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Graphical Abstract
We have developed and validated combinatorial treatment for metastatic ovarian cancer which
consists of two monotherapies administered sequentially via intraperitoneal route for three
cycles: (1) siRNA-loaded nanoparticles aimed to suppress DJ-1 protein, and (2) the
chemotherapy agent, cisplatin. DJ-1 suppression by siRNA can simultaneously interfere with the
expression of multiple oncogenic proteins responsible for ovarian cancer cells survival,
migration, proliferation and resistance to platinum-based drugs. The developed therapy
eradicated metastatic ovarian cancer tumors from the mice, and there was no cancer recurrence
detected during the duration of the study.

29

Graphics Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Figure 7

